img-antibody-drug-conjugate-services-white-paper1920x640
Whitepaper

Preclinical screening platforms for antibody-drug conjugate therapeutics

Antibody Drug Conjugates (ADCs) are a hot topic in drug discovery as one of the most rapidly expanding oncology therapeutic categories.

Learn more about ADCs and the role that screening can play to help advance the discovery process for ADC therapeutic candidates in this white paper.

You will learn about:

  • An overview of ADCs, why they're important in oncology drug discovery and key considerations in ADC design
  • The role of cell panel screening for ADC-based combination therapies
  • The importance of screening genetic drives and mechanisms of action and resistance
  • Optimization of ADC structure using immune cell-based screening

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Preclinical screening platforms for antibody-drug conjugate therapeutics

Download Whitepaper